94 related articles for article (PubMed ID: 26927018)
1. Identification of an active metabolite of PAR-1 antagonist RWJ-58259 and synthesis of analogues to enhance its metabolic stability.
Robinson E; Knight E; Smoktunowicz N; Chambers RC; Inglis GG; Chudasama V; Caddick S
Org Biomol Chem; 2016 Mar; 14(12):3198-201. PubMed ID: 26927018
[TBL] [Abstract][Full Text] [Related]
2. RWJ-58259: a selective antagonist of protease activated receptor-1.
Damiano BP; Derian CK; Maryanoff BE; Zhang HC; Gordon PA
Cardiovasc Drug Rev; 2003; 21(4):313-26. PubMed ID: 14647534
[TBL] [Abstract][Full Text] [Related]
3. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.
Andrade-Gordon P; Derian CK; Maryanoff BE; Zhang HC; Addo MF; Cheung Wm ; Damiano BP; D'Andrea MR; Darrow AL; de Garavilla L; Eckardt AJ; Giardino EC; Haertlein BJ; McComsey DF
J Pharmacol Exp Ther; 2001 Jul; 298(1):34-42. PubMed ID: 11408522
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
Derian CK; Damiano BP; Addo MF; Darrow AL; D'Andrea MR; Nedelman M; Zhang HC; Maryanoff BE; Andrade-Gordon P
J Pharmacol Exp Ther; 2003 Feb; 304(2):855-61. PubMed ID: 12538843
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of new peptide-based ureas and thioureas as potential antagonists of the thrombin receptor PAR1.
Ventosa-Andrés P; Valdivielso AM; Pappos I; García-López MT; Tsopanoglou NE; Herranz R
Eur J Med Chem; 2012 Dec; 58():98-111. PubMed ID: 23123726
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
7. Discovery and optimization of a novel series of thrombin receptor (par-1) antagonists: potent, selective peptide mimetics based on indole and indazole templates.
Zhang HC; Derian CK; Andrade-Gordon P; Hoekstra WJ; McComsey DF; White KB; Poulter BL; Addo MF; Cheung WM; Damiano BP; Oksenberg D; Reynolds EE; Pandey A; Scarborough RM; Maryanoff BE
J Med Chem; 2001 Mar; 44(7):1021-4. PubMed ID: 11297447
[No Abstract] [Full Text] [Related]
8. Blockage of protease-activated receptor 1 ameliorates heat-stress induced intestinal high permeability and bacterial translocation.
Xu QL; Guo XH; Liu JX; Chen B; Liu ZF; Su L
Cell Biol Int; 2015 Apr; 39(4):411-7. PubMed ID: 25492552
[TBL] [Abstract][Full Text] [Related]
9. Comments on "Blockade of angiogenesis by small molecule antagonists to protease-activated receptor-1: association with endothelial cell growth suppression and induction of apoptosis".
Di Serio C; Pellerito S; Tarantini F
J Pharmacol Exp Ther; 2008 Jan; 324(1):404-5; author reply 406-7. PubMed ID: 18094323
[No Abstract] [Full Text] [Related]
10. Design and synthesis of potent PAR-1 antagonists based on vorapaxar.
Fan M; Han M; Xia Y; Zhang Y; Chu Y; Bai G; Li W; Li J; Zhao L; He Y; Ma X; Duan Z
Bioorg Med Chem Lett; 2020 Apr; 30(8):127046. PubMed ID: 32122739
[TBL] [Abstract][Full Text] [Related]
11. Thrombin receptor (PAR-1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide.
Zhang HC; McComsey DF; White KB; Addo MF; Andrade-Gordon P; Derian CK; Oksenberg D; Maryanoff BE
Bioorg Med Chem Lett; 2001 Aug; 11(16):2105-9. PubMed ID: 11514149
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of novel and potent vorapaxar analogues.
Knight E; Robinson E; Smoktunowicz N; Chambers RC; Aliev AE; Inglis GG; Chudasama V; Caddick S
Org Biomol Chem; 2016 Mar; 14(12):3264-74. PubMed ID: 26932831
[TBL] [Abstract][Full Text] [Related]
13. Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin.
Fang M; Kovács KJ; Fisher LL; Larson AA
J Physiol; 2003 Jun; 549(Pt 3):903-17. PubMed ID: 12717003
[TBL] [Abstract][Full Text] [Related]
14. In vitro structure-activity relationship and in vivo characterization of 1-(aryl)-3-(4-(amino)benzyl)urea transient receptor potential vanilloid 1 antagonists.
Perner RJ; DiDomenico S; Koenig JR; Gomtsyan A; Bayburt EK; Schmidt RG; Drizin I; Zheng GZ; Turner SC; Jinkerson T; Brown BS; Keddy RG; Lukin K; McDonald HA; Honore P; Mikusa J; Marsh KC; Wetter JM; George KS; Jarvis MF; Faltynek CR; Lee CH
J Med Chem; 2007 Jul; 50(15):3651-60. PubMed ID: 17583335
[TBL] [Abstract][Full Text] [Related]
15. (R)-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo.
Surowy CS; Neelands TR; Bianchi BR; McGaraughty S; El Kouhen R; Han P; Chu KL; McDonald HA; Vos M; Niforatos W; Bayburt EK; Gomtsyan A; Lee CH; Honore P; Sullivan JP; Jarvis MF; Faltynek CR
J Pharmacol Exp Ther; 2008 Sep; 326(3):879-88. PubMed ID: 18515644
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
Souers AJ; Gao J; Wodka D; Judd AS; Mulhern MM; Napier JJ; Brune ME; Bush EN; Brodjian SJ; Dayton BD; Shapiro R; Hernandez LE; Marsh KC; Sham HL; Collins CA; Kym PR
Bioorg Med Chem Lett; 2005 Jun; 15(11):2752-7. PubMed ID: 15911251
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.
Gilmore JL; Sheppeck JE; Wang J; Dhar TG; Cavallaro C; Doweyko AM; Mckay L; Cunningham MD; Habte SF; Nadler SG; Dodd JH; Somerville JE; Barrish JC
Bioorg Med Chem Lett; 2013 Oct; 23(19):5448-51. PubMed ID: 23916594
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of a TRPV1 receptor antagonist.
Yu S; Haight A; Kotecki B; Wang L; Lukin K; Hill DR
J Org Chem; 2009 Dec; 74(24):9539-42. PubMed ID: 19928811
[TBL] [Abstract][Full Text] [Related]
19. Octahydrocyclopenta[c]pyridine and octahydrocyclopenta[c]pyran analogues as a protease activated receptor 1 (PAR1) antagonist.
Wadood A; Kim H; Park CM; Song JH; Lee S
Arch Pharm Res; 2015 Nov; 38(11):2029-41. PubMed ID: 26068939
[TBL] [Abstract][Full Text] [Related]
20. 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists.
Haydar SN; Yun H; Andrae PM; Mattes J; Zhang J; Kramer A; Smith DL; Huselton C; Graf R; Aschmies S; Schechter LE; Comery TA; Robichaud AJ
J Med Chem; 2010 Mar; 53(6):2521-7. PubMed ID: 20170099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
